medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-4-22-26medalphabet-3665Research ArticleСтатьиАнализ содержания биомаркеров эндотелиальной дисфункции у пациентов с окклюзиями сосудов сетчатки различного генезаAnalysis of endothelial dysfunction biomarkers in patients with various cases of retinal vessel occlusionhttps://orcid.org/0000-0003-1685-3713БельскаяК. И.BelskayaK. I.

Бельская Ксения Игоревна, врач офтальмолог; соискатель кафедры офтальмологии

Москва

Belskaya Ksenia I., ophthalmologist; applicant for the Dept of Ophthalmology

Moscow

belskaia.ki@gmail.comhttps://orcid.org/0000-0001-5081-414XМошетоваЛ. К.MoshetovaL. K.

Мошетова Лариса Константиновна, д. м. н., профессор, академик РАН, заведующая кафедрой офтальмологии, президент

Москва

Moshetova Larisa K., DM Sci (habil.), professor, academician of the Russian Academy of Sciences, head of Dept of Ophthalmology, president

Moscow

moshetovalk@yandex.ruhttps://orcid.org/0000-0001-6528-1059КазаковС. П.KazakovS. P.

Казаков Сергей Петрович, д. м. н., начальник центра клинической лабораторной диагностики, главный лаборант; проф. кафедры клинической лабораторной диагностики и патологической анатомии; президент российской ассоциации медицинской лабораторной диагностики (РАМЛД)

РИНЦ: 5560–3931, Scopus ID –57211351588, WoS Researcher ID: C-6644–2018

Москва

Kazakov Sergey P., DM Sci (habil.), head of the Center for Clinical Laboratory Diagnostics, chief laboratory assistant; professor at Dept of Clinical Laboratory Diagnostics and Pathological Anatomy, president of Russian Association of Medical Laboratory Diagnostics (RAMLD)

RSCI: 5560–3931, Scopus ID –57211351588, WoS Researcher ID: C-6644–2018

Moscow

rmapo.kafimm@mail.ruМГОЦ ГБУЗ «ГКБ имени С. П. Боткина ДЗМ»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияCity Clinical Hospital named after S. P. Botkin; Russian Medical Academy of Continuous Professional EducationRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияRussian Medical Academy of Continuous Professional EducationRussian FederationФГБУ «ГВКГ имени Н. Н. Бурденко» Минобороны России; ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства» РоссииРоссияMain Military Clinical Hospital named after academician N. N. Burdenko Russian Defense Ministry; Federal Research and Clinical Center of specialized types of health care and medical technology of the Federal Medical and Biological AgencyRussian Federation20240905202404Современная лаборатория (1)2226Copyright © Бельская К.И., Мошетова Л.К., Казаков С.П., 20242024Бельская К.И., Мошетова Л.К., Казаков С.П.Belskaya K.I., Moshetova L.K., Kazakov S.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3665

Окклюзия сосудов сетчатки – тяжелое сосудистое состояние сетчатки, ведущее к значительному снижению зрения и слепоте. Патогенетически важное значение в развитии тромбоза играет эндотелиальная дисфункция. Целью настоящего исследования была количественная оценка биомаркеров дисфункции эндотелия. Было исследовано содержание VEGF слезной жидкости и гомоцистеина сыворотки крови в 3 группах – в группе I (пациенты с окклюзией центральной вены сетчатки), группе II (пациенты с окклюзией центральной артерии сетчатки) и группе контроля (пациенты без сосудистых нарушений). Группы были сопоставимы по полу и возрасту. Результаты показали повышенное содержания VEGF и гомоцистеина у пациентов с окклюзией ЦВС. Содержание маркеров у пациентов с окклюзией центральной артерии сетчатки было достоверно ниже I группы, однако достоверно выше группы контроля. Результаты показывают вовлеченность эндотелия в местный тромботический процесс.

Retinal vascular occlusion is a severe vascular condition of the retina, leading to a significant decrease in vision and blindness. Endothelial dysfunction plays a pathogenetically important role in the development of thrombosis. The aim of this study was to quantify biomarkers of endothelial dysfunction. The content of VEGF tear fluid and serum homocysteine was studied in 3 groups – in group I (patients with occlusion of the central retinal vein), group II (patients with occlusion of the central retinal artery) and control group (patients without vascular disorders). The groups were comparable in gender and age. The results showed an increased content of VEGF and homocysteine in patients with the central artery of the retina occlusion. The content of markers in patients with the central artery of the retina occlusion was significantly lower than group I, but significantly higher than the control group. The results show the involvement of the endothelium in the local thrombotic process.

окклюзия сосудов сетчаткиваскулярный эндотелиальный фактор ростагомоцистеинretinal vessel occlusionvascular endothelial growth factorhomocysteineReferencesKlein R., Moss S.E., Meuer S.M., Klein B.E. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008; 126(4):513–8.https://doi.org/10.1001/archopht.126.4.513Klein R., Moss S.E., Meuer S.M., Klein B.E. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008; 126(4):513–8.https://doi.org/10.1001/archopht.126.4.513The Eye Disorders Case-Control Study Group Risk Factors for Central Retinal Vein Occlusion. Arch Ophthalmol 1996; (114): 545–54.https://doi.org/10.1001/archopht.1996.01100130537006The Eye Disorders Case-Control Study Group Risk Factors for Central Retinal Vein Occlusion. Arch Ophthalmol 1996; (114): 545–54.https://doi.org/10.1001/archopht.1996.01100130537006Elman M.J., Bhatt A.K., Quinlan P.M., Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990; 97(11):1543–8.https://doi.org/10.1016/s0161–6420(90)32379–5Elman M.J., Bhatt A.K., Quinlan P.M., Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990; 97(11):1543–8.https://doi.org/10.1016/s0161–6420(90)32379–5Bertelsen M., Linneberg A., Christfferson N, Vorum H, Cade E, Larsen M. Mortality in patients with central retinal vein occlusion. Ophthalmology 2014; (12):637–642.https://doi.org/10.1016/j.ophtha.2013.07.025Bertelsen M., Linneberg A., Christfferson N, Vorum H, Cade E, Larsen M. Mortality in patients with central retinal vein occlusion. Ophthalmology 2014; (12):637–642.https://doi.org/10.1016/j.ophtha.2013.07.025Koizumi H., Ferrara D.C., Brue C., Spaide R.F. Central retinal vein occlusion case-control study. Am J Ophthalmol 2007; (144):858–63.https://doi.org/10.1016/j.ajo.2007.07.036Koizumi H., Ferrara D.C., Brue C., Spaide R.F. Central retinal vein occlusion case-control study. Am J Ophthalmol 2007; (144):858–63.https://doi.org/10.1016/j.ajo.2007.07.036Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 1992; (99):509–14.https://doi.org/10.1016/s0161–6420(92)31940–2Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 1992; (99):509–14.https://doi.org/10.1016/s0161–6420(92)31940–2Shahsuvaryan M.L., Melkonyan A.K. Central retinal vein occlusion risk profile: a case-control study. Eur J Ophthalmol 2003; (13):445–52. https://doi.org/10.1177/112067210301300505Shahsuvaryan M.L., Melkonyan A.K. Central retinal vein occlusion risk profile: a case-control study. Eur J Ophthalmol 2003; (13):445–52. https://doi.org/10.1177/112067210301300505Wang Y.X., Zhang J.S., You QS, Xu.L., Jonas J.B. Ocular diseases and 10-year mortality: The Beijing Eye Study 2001.20Acta Ophthalmol. Acta Ophthalmol 2014; 92(6):424–8. https://doi.org/10.1111/aos.12370Wang Y.X., Zhang J.S., You QS, Xu.L., Jonas J.B. Ocular diseases and 10-year mortality: The Beijing Eye Study 2001.20Acta Ophthalmol. Acta Ophthalmol 2014; 92(6):424–8. https://doi.org/10.1111/aos.12370Dodson, P.M., Galton, D.J., Hamilton, A.M. et al. Retinal Vein Occlusion and the Prevalence of Lipoprotein Abnormalities. Br J Ophthalmol 1982; (66): 161–164. https://doi.org/10.1136/bjo.66.3.161Dodson, P.M., Galton, D.J., Hamilton, A.M. et al. Retinal Vein Occlusion and the Prevalence of Lipoprotein Abnormalities. Br J Ophthalmol 1982; (66): 161–164. https://doi.org/10.1136/bjo.66.3.161Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.Петрищев H. Н. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция. – СПб.: Изд-во СПбГМУ, 2003. – 184 с.Petrishchev N. N. Endothelial dysfunction. Causes, mechanisms, pharmacological correction. – St. Petersburg: Publishing house of St. Petersburg State Medical University, 2003. – 184 p.Тульцева С. Н. Эндотелиальные регуляторы фибринолиза у больных с тромбозом вен сетчатки. Офтальмологические ведомости. 2009; (2):4–11.Tultseva S. N. Endothelial regulators of fibrinolysis in patients with retinal vein thrombosis. Ophthalmological bulletin. 2009; (2):4–11.FlammerJl, KonieczkaK, FlammerAJ. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J.2013; (4): 1–14.https://doi.org/10.1186/1878–5085–4–14FlammerJl, KonieczkaK, FlammerAJ. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J.2013; (4): 1–14.https://doi.org/10.1186/1878–5085–4–14Haufschild T, Prunte C, Messerli J, Flammer JIncreased endothelin-1 plasma level in young adults with retinal vascular occlusive diseases. Klin Monbl Augenheilkd.2004; 221(5):357–359.https://doi.org/10.1055/s-2004–812813Haufschild T, Prunte C, Messerli J, Flammer JIncreased endothelin-1 plasma level in young adults with retinal vascular occlusive diseases. Klin Monbl Augenheilkd.2004; 221(5):357–359.https://doi.org/10.1055/s-2004–812813Kang MH1, Balaratnasingam C, Yu PK, Morgan WH, McAllister IL, Cringle SJ, Yu DY. Morphometric characteristics of central retinal artery and vein endothelium in the normal human optic nerve head. Invest Ophthalmol Vis Sci.2011.52(3):1359–1367.https://doi.org/10.1167/iovs.10–6366Kang MH1, Balaratnasingam C, Yu PK, Morgan WH, McAllister IL, Cringle SJ, Yu DY. Morphometric characteristics of central retinal artery and vein endothelium in the normal human optic nerve head. Invest Ophthalmol Vis Sci.2011.52(3):1359–1367.https://doi.org/10.1167/iovs.10–6366Lip P.L., Blann A.D., Jones A.F., Lip G.Y. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye (Lond).1998;(12):245–51.https://doi.org/10.1038/eye.1998.58Lip P.L., Blann A.D., Jones A.F., Lip G.Y. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye (Lond).1998;(12):245–51.https://doi.org/10.1038/eye.1998.58Rehak M., Wiedemann P. Retinal vein thrombosis: pathogenesis and management. JThromb Haemost.2010; (8):1886–1894.https://doi.org/10.1111/j.1538–7836.2010.03909.xRehak M., Wiedemann P. Retinal vein thrombosis: pathogenesis and management. JThromb Haemost.2010; (8):1886–1894.https://doi.org/10.1111/j.1538–7836.2010.03909.xTananoIl, Nagaoka T., Sogawa K., Tani T, Omae T., Nakabayashi S., Ishibazawa A., Yoshida A. Impaired systemic vascular endothelial function in patients with branch retinal vein occlusion. Curr Eye Res.2013; (38):114–118.https://doi.org/10.3109/02713683.2012.738460TananoIl, Nagaoka T., Sogawa K., Tani T, Omae T., Nakabayashi S., Ishibazawa A., Yoshida A. Impaired systemic vascular endothelial function in patients with branch retinal vein occlusion. Curr Eye Res.2013; (38):114–118.https://doi.org/10.3109/02713683.2012.738460Wautier J.L., WautierMP.Molecular basis of erythrocyte adhesion to endothelial cells in diseases. Clin Hemorheol Microcirc.2013; (53):11–21.https://doi.org/10.3233/ch-2012–1572Wautier J.L., WautierMP.Molecular basis of erythrocyte adhesion to endothelial cells in diseases. Clin Hemorheol Microcirc.2013; (53):11–21.https://doi.org/10.3233/ch-2012–1572Wu K. K., Thiagarajan P. Role of endothelium in thrombosis and hemostasis //Annu Rev Med.1996;(47): P. 315–331.https://doi.org/10.1146/annurev.med.47.1.315Wu K. K., Thiagarajan P. Role of endothelium in thrombosis and hemostasis //Annu Rev Med.1996;(47): P. 315–331.https://doi.org/10.1146/annurev.med.47.1.315Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. Эндотелиальная дисфункция при сердечной недостаточности: возможности терапии ингибиторами АПФ Кардиология. 2001; (41):100–104.Belenkov Yu.N., Mareev V. Yu., Ageev F. T. Endothelial dysfunction in heart failure: possibilities of therapy with ACE inhibitors Cardiology. 2001; (41):100–104.Задионченко B. C., Адашева Т. В., Сандомирская А. Г. Дисфункция эндотелия и артериальная гипертония: терапевтические возможности. Русский Медицинский Журнал. 2002; (1):11–16.Zadionchenko B. S., Adasheva T. V., Sandomirskaya A. G. Endothelial dysfunction and arterial hypertension: therapeutic options. Russian Medical Journal. 2002; (1):11–16.Крамарь Т. В. Патофизиологические аспекты воспалительного и невоспалительного неоангиогенеза. Крымский журнал экспериментальной и клинической медицины.2020; (10):59–63.https://doi.org/10.37279/2224–6444–2020–10–3–59–63Kramar T. V. Pathophysiological aspects of inflammatory and non-inflammatory neoangiogenesis. Crimean Journal of Experimental and Clinical Medicine.2020; (10):59–63. https://doi.org/10.37279/2224–6444–2020–10–3–59–63Yoshimura T. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases / T. Yoshimura, K. H. Sonoda, M. Sugaharaetal. PLoS ONE. – 2009. (12):8158. https://doi.org/10.1371/journal.pone.0008158Yoshimura T. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases / T. Yoshimura, K. H. Sonoda, M. Sugaharaetal. PLoS ONE. – 2009. (12):8158. https://doi.org/10.1371/journal.pone.0008158Bhisitkil R.B. Vascular endothelial growth factor biology: clinical implications for ocular treatment. Br J Ophthalmol. 2006;90(12):1542–1547. doi: 10.1136/bjo.2006.098426.Bhisitkil R.B. Vascular endothelial growth factor biology: clinical implications for ocular treatment. Br J Ophthalmol. 2006;90(12):1542–1547. doi: 10.1136/bjo.2006.098426.Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its reseptors. Nat Med. 2003;9(6):669–676.https://doi.org/10.1038/nm0603–669Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its reseptors. Nat Med. 2003;9(6):669–676.https://doi.org/10.1038/nm0603–669Schligemann R.O., Van Hinsberg V.W. Role of vascular permeability factor/ vascular endothelial growth factor in eye disease. Br J Ophthalmol. 1997;81(6):501–512.https://doi.org/10.1136/bjo.81.6.501Schligemann R.O., Van Hinsberg V.W. Role of vascular permeability factor/ vascular endothelial growth factor in eye disease. Br J Ophthalmol. 1997;81(6):501–512.https://doi.org/10.1136/bjo.81.6.501Campochiaro P. A., Hafiz G., Shah S. M. et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator // Mol. Ther. 2008;(16):791–799.https://doi.org/10.1038/mt.2008.10Campochiaro P. A., Hafiz G., Shah S. M. et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator // Mol. Ther. 2008;(16):791–799.https://doi.org/10.1038/mt.2008.10Branch Vein Occlusion Study Group. Argonlaser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch. Ophthalmol.1996;104(1):34–41.https://doi.org/10.1001/archopht.1986.01050130044017Branch Vein Occlusion Study Group. Argonlaser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch. Ophthalmol.1996;104(1):34–41.https://doi.org/10.1001/archopht.1986.01050130044017Gutman F. A., Zegarra H. Macular edema secondarу to occlusion of the retinal veins. Surv. Opthalmol. 1984;(28):462–470.https://doi.org/10.1016/0039–6257(84)90228–5Gutman F. A., Zegarra H. Macular edema secondarу to occlusion of the retinal veins. Surv. Opthalmol. 1984;(28):462–470.https://doi.org/10.1016/0039–6257(84)90228–5Шевченко, О. П. Гомоцистеин и его роль в клинической практике (лекция). Клиническая лабораторная диагностика. 2008; (11): 25–32.Shevchenko, O. P. Homocysteine and its role in clinical practice (lecture). Clinical laboratory diagnostics. 2008; (11): 25–32.Bonitton-Kopp. С. Early carotid atherosclerosis in healthy middle-aged women. Kopp. Ibid. 1993;(24):1837–1843. https://doi.org/10.1161/01.str.24.12.1837Bonitton-Kopp. С. Early carotid atherosclerosis in healthy middle-aged women. Kopp. Ibid. 1993;(24):1837–1843. https://doi.org/10.1161/01.str.24.12.1837O. Tamai, H. Matsuoka, H. Itabe.Single LDL apheresis improves endothelium – dependent vasodilatation in hypercholesterolemic humans. Circulation. 1997;(95):76–82. https://doi.org/10.1161/01.cir.95.1.76O. Tamai, H. Matsuoka, H. Itabe.Single LDL apheresis improves endothelium – dependent vasodilatation in hypercholesterolemic humans. Circulation. 1997;(95):76–82. https://doi.org/10.1161/01.cir.95.1.76Shepherd, S. M. Cobbe, I. Ford. For the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995;(333):1301–1307.https://doi.org/10.1056/nejm199511163332001Shepherd, S. M. Cobbe, I. Ford. For the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995;(333):1301–1307.https://doi.org/10.1056/nejm199511163332001Hankey G. J. Homocysteine and vascular disease. Lancet. 1999;(354):407–413. https://doi.org/10.1016/s0140–6736(98)11058–9Hankey G. J. Homocysteine and vascular disease. Lancet. 1999;(354):407–413. https://doi.org/10.1016/s0140–6736(98)11058–9MacMahon M., Kirkpatrick C. Nutr Metab Cardiovasc. Dis. 2000;(10):195–203.MacMahon M., Kirkpatrick C. Nutr Metab Cardiovasc. Dis. 2000;(10):195–203.М. Bots, L. Launer, J. Lindemans.Homocysteine and short–term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study Arch. Intern. Med. 1999;(1):138–159. https://doi.org/10.1001/archinte.159.1.38.М. Bots, L. Launer, J. Lindemans.Homocysteine and short–term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study Arch. Intern. Med. 1999;(1):138–159. https://doi.org/10.1001/archinte.159.1.38.Shevchenko O. P., Olefrienko G. A. Gipergomocisteinemijaiee klinicheskoe znachenie. Laboratorija. 2002;(1):3–7.Shevchenko O. P., Olefrienko G. A. Gipergomocisteinemijaiee klinicheskoe znachenie. Laboratorija. 2002;(1):3–7.Shmeleva V. M. Gipergomocisteinemijai tromboz // Tromboz, gemostazireologija. 2000;(4):26–29.Shmeleva V. M. Gipergomocisteinemijai tromboz // Tromboz, gemostazireologija. 2000;(4):26–29.Arnadottir M. Homocysteine in renal disease, in Homocysteine in health and disease. Cambridge University Press, Cambridge. 2001;321–330.Arnadottir M. Homocysteine in renal disease, in Homocysteine in health and disease. Cambridge University Press, Cambridge. 2001;321–330.Zagzag D., Zhong H., Scalzitti J. M., Laughner E., Simons J. W., Semenza G. L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88(11):2606–2618.https://doi.org/10.1002/1097–0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-WZagzag D., Zhong H., Scalzitti J. M., Laughner E., Simons J. W., Semenza G. L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88(11):2606–2618.https://doi.org/10.1002/1097–0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W

The authors declare that there are no conflicts of interest present.